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Summary
Multiple endocrine neoplasia type 1 (MEN1) is an au-
tosomal dominant disorder characterized by tumors of
the parathyroids, pancreatic islets, and anterior pituitary.
The MEN1 gene, on chromosome 11q13, has recently
been cloned, and mutations have been identified. We
have characterized such MEN1 mutations, assessed the
reliability of SSCP analysis for the detection of these
mutations, and estimated the age-related penetrance for
MEN1. Sixty-three unrelated MEN1 kindreds (195 af-
fected and 396 unaffected members) were investigated
for mutations in the 2,790-bp coding region and splice
sites, by SSCP and DNA sequence analysis. We identified
47 mutations (12 nonsense mutations, 21 deletions, 7
insertions, 1 donor splice-site mutation, and 6 missense
mutations), that were scattered throughout the coding
region, together with six polymorphisms that had het-
erozygosity frequencies of 2%–44%. More than 10%
of the mutations arose de novo, and four mutation hot
spots accounted for 125% of the mutations. SSCP was
found to be a sensitive and specific mutational screening
method that detected 185% of the mutations. Two hun-
dred and one MEN1 mutant-gene carriers (155 affected
and 46 unaffected) were identified, and these helped to
define the age-related penetrance ofMEN1 as 7%, 52%,
87%, 98%, 99%, and 100% at 10, 20, 30, 40, 50, and
60 years of age, respectively. These results provide the
basis for a molecular-genetic screening approach that
will supplement the clinical evaluation and genetic coun-
seling of members of MEN1 families.
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Introduction
Multiple endocrine neoplasia type 1 (MEN1; MIM
131100 [http://www3.ncbi.nlm.nih.gov:80/htbin-post/
Omim/dispmim?131100]) is an autosomal dominant
disorder characterized by the combined occurrence of
tumors of the parathyroid glands, the pancreatic islet
cells, and the anterior pituitary (Wermer 1954; Thakker
1995; Trump et al. 1996). In addition, adrenal cortical
tumors, carcinoid tumors, and lipomas have also been
observed in association with MEN1. The autosomal
dominant inheritance of this disease indicates that 50%
of the children of a patient with MEN1 will have the
mutant gene and be at a high risk of developing endo-
crine tumors. The identification of such individuals, to-
gether with an earlier detection of the development of
tumors, may help to reduce the morbidity and mortality
of these patients (Trump et al. 1996). The recent iso-
lation of the MEN1 gene in conjunction with the char-
acterization of mutations in MEN1 patients (Agarwal
et al. 1997; Chandrasekharappa et al. 1997; European
Consortium on MEN1 1997b), may facilitate this
assessment.
The MEN1 gene, which represents a putative tumor-
suppressor gene (Varmus 1984; Thakker 1993; Brown
and Solomon 1997), had been localized, by genetic-map-
ping studies, to chromosome 11q13 (Larsson et al. 1988;
Thakker et al. 1989), within a !300-kb region flanked
centromerically by PYGM and telomerically by
D11S1783 (European Consortium on MEN1 1997a).
Characterization of genes from this region led to the
identification of the MEN1 gene (Chandrasekharappa
et al. 1997; European Consortium on MEN1 1997b),
which consists of 10 exons (fig. 1) that encode a novel
610-amino-acid protein, referred to as “MENIN”
(Chandrasekharappa et al. 1997). The functional role of
MENIN, which does not have homologies to other pro-
teins that are involved in cell proliferation and control
of the cell cycle (Pang and Thakker 1994; Brown and
Solomon 1997; Chandrasekharappa et al. 1997; Euro-
pean Consortium on MEN1 1997b), remains to be elu-
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Figure 1 Schematic representation of the genomic organization of the MEN1 gene. The human MEN1 gene consists of 10 exons that
span 19 kb of genomic DNA and encodes a 610-amino-acid protein (Chandrasekharappa et al. 1997; European Consortium on MEN1 1997b).
The 1.83 kb coding region is organized into nine exons (exons 2–10 [hatched boxes]) and eight introns (thicker horizontal line [not drawn to
scale]). The sizes of the exons (range 42–1,297 bp) and introns (range 80–1,564 bp) are shown, and the start (ATG) and stop (TGA) sites in
exons 2 and 10, respectively, are indicated. Exon 1, the 5′ part of exon 2 and the 3′ part of exon 10 are untranslated (nonhatched boxes). The
locations of 15 pairs of the primers (arrows [F  forward; and R  reverse]) that were used to amplify the exons and exon/intron boundaries
are shown. The sites of the 47 mutations (12 nonsense mutations, 21 deletions, 5 insertions, 2 deletional insertions, 1 donor splice-site mutation,
and 6 missense mutations) and of six different polymorphisms are shown below; the details of each of these are provided in table 1.
cidated. However, inactivating mutations of the MEN1
gene (Agarwal et al. 1997; Chandrasekharappa et al.
1997; European Consortium on MEN1 1997b), which
is ubiquitously expressed as a 2.9-kb transcript, with an
additional 4.2-kb transcript being present in pancreas
and thymus (European Consortium on MEN1 1997b),
are associated with the development of endocrine tumors
in MEN1 families. We have therefore undertaken studies
to characterize the spectrum of MEN1 mutations, with
the aims of evaluating the reliability of SSCP for their
detection and of defining the age-related penetrance of
this disorder, so as to supplement the clinical evaluation
of MEN1 patients and their families.
Patients and Methods
Patients
The families of 63 unrelated MEN1 probands were
ascertained, and a total of 947 members (479 males and
468 females; age range 2–89 years [mean  SD 36 
18 years]) were assessed (Trump et al. 1996). MEN1
was diagnosed in a family if two or more MEN1-related
tumors had been demonstrated in at least one individual;
other related members were considered affected only if
they had clinical, radiological, and/or surgical evidence
of MEN1-related tumors or repeated biochemical evi-
dence of one of the MEN1-associated tumors, as re-
ported elsewhere (Trump et al. 1996). A family history
of MEN1 could be established in 57 of the probands
(family-size range 3–80 members), and there were 269
affected members (134 males and 135 females) and 672
unaffected members (342 males and 330 females). A
familial basis for MEN1 could not be established in six
of the MEN1 probands (three males and three females;
age range 32–52 years), all of whom had at least three
MEN1-related tumors. Venous blood samples were ob-
tained from 189 affected members (92 males and 97
females; age range 8–85 years [mean  SD 40  16
years]) and 396 unaffected members (184 males and 212
females; age range 2–89 years [mean  SD 34  19
years]) of the 57 MEN1 families and from the 6 non-
familial MEN1 patients. A total of 342 tumors occurred
in the 195 affected members (189 familial and 6 non-
familial), and these consisted of 179 parathyroid tumors,
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81 pancreatic islet–cell tumors (52 gastrinomas, 17 in-
sulinomas, 6 glucagonomas, and 6 nonfunctioning tu-
mors), 66 anterior-pituitary tumors (55 prolactinomas,
4 somatotrophinomas, 3 corticotrophinomas, and 4
nonfunctioning tumors), 7 carcinoid tumors, 6 adrenal
cortical tumors, and 3 lipomas.
DNA Hybridization and Microsatellite Polymorphism
Analysis
DNA from leukocytes was prepared by standard
methods (Thakker et al. 1989), and RFLPs and micro-
satellite polymorphisms were detected by methods de-
scribed elsewhere (Thakker et al. 1989; Pang et al. 1996;
European Consortium on MEN1 1997c). Ten polymor-
phic microsatellite loci (CNTF, D11S480, D11S1883,
D11S457, PYGM, D11S449, D11S913, D11S97, INT2,
and D11S533) from chromosome 11q13 were used as
described elsewhere (Pang et al. 1996; European Con-
sortium on MEN1 1997c) to determine the haplotypes
around the MEN1 locus, and the five loci (D11S1883,
PYGM, D11S449, D11S97, and D11S533) each with
eight or more alleles and a heterozygosity 175% (Pang
et al. 1996; European Consortium on MEN1 1997c)
were used to exclude nonpaternity, as described else-
where (Pearce et al. 1995; Pang et al. 1996).
DNA Sequence Analysis of the MEN1 Gene
DNA sequence abnormalities were initially sought in
each of the 63 MEN1 probands, by SSCP analysis
(Grompe 1993; Pearce et al. 1995; Lloyd et al. 1997).
Fifteen pairs of primers (European Consortium on
MEN1 1997b) were used for the PCR amplification of
the nine coding exons of the MEN1 gene (fig. 1) and of
their corresponding 16 exon/intron boundaries, with
conditions as described elsewhere (European Consor-
tium on MEN1 1997b). The PCR products were ana-
lyzed for SSCPs, by the Phast electrophoresis system
(Pharmacia Biotech), as reported elsewhere (Pearce et al.
1995; Lloyd et al. 1997), by the method of silver stain-
ing, with 0.025 M aqueous silver nitrate for 10 min.
Genomic DNA samples from 10 unrelated normal in-
dividuals were also used, as controls, in the SSCP anal-
ysis. The DNA sequence of abnormal SSCPs was deter-
mined by the use of Taq polymerase cycle sequencing
and a semiautomated detection system (ABI 373A se-
quencer; Applied Biosystems) (Pearce et al. 1995; Lloyd
et al. 1996, 1997). In addition, these DNA sequence
abnormalities were confirmed either by restriction-en-
zyme analysis of genomic PCR products obtained by the
use of the appropriate primers, or by allele-specific oli-
gonucleotide (ASO) hybridization analysis (Thakker et
al. 1993), or by agarose-gel electrophoresis (GE) (Pearce
et al. 1995; Lloyd et al. 1996, 1997). These DNA se-
quence abnormalities were also demonstrated to coseg-
regate with the disorder and to be absent as common
polymorphisms in DNA obtained from 55 unrelated
normal individuals (27 males and 28 females). In order
to assess the sensitivity and specificity of SSCP analysis
in the detection of the mutations, the DNA sequence of
the entire 2.79 kb of the coding sequence, together with
the exon/intron boundaries of the MEN1 gene, was de-
termined and compared with the SSCP results obtained
in 10 MEN1 probands; the mutations in 3 of these pro-
bands, from families 18, G/87, and H/94, have been
reported elsewhere (European Consortium on MEN1
1997b). Each of the 10 probands had developed para-
thyroid, pancreatic islet–cell, and anterior-pituitary tu-
mors. Southern and northern blot hybridization analyses
were used to assess, respectively, genomic deletions of
the MEN1 gene and the associated abnormal sizes of
the mRNA transcripts, as described elsewhere (Thakker
et al. 1993; Pearce et al. 1995; Lloyd et al. 1996, 1997;
European Consortium on MEN1 1997b).
Statistical Analysis
The means, SDs, standard error of the means, differ-
ences between means, and x2 values were calculated by
the Microsoft Excel program. In addition, nonparamet-
ric tests were performed by use of the Mann-Whitney
U-test with the STATA program.
Results
Mutational Detection by SSCP
The analysis of 945 SSCPs obtained from the 63 un-
related MEN1 patients revealed a total of 90 abnormal
bands (fig. 2). Twenty-seven of the MEN1 patients had
one abnormal SSCP, 30 patients had two abnormal
SSCPs, 1 patient had three abnormal SSCPs, and 5 pa-
tients had no SSCP abnormalities. The occurrence of two
or more SSCP abnormalities in a patient suggested the
occurrence of polymorphisms, and DNA sequence anal-
ysis of all the 90 SSCP abnormalities revealed that 46
(51%) of the SSCP abnormalities were mutations (table
1 and fig. 1), that 38 (42%) were the result of six dif-
ferent polymorphisms, and that 6 (7%) were associated
with a normal DNA sequence and thus were false pos-
itives. In addition, DNA sequence analysis of the entire
2.79-kb coding region and exon/intron boundaries in 10
MEN1 probands revealed the presence of eight muta-
tions—Trp183stop, Glu388stop, 83–84del4bp (which
was observed twice), 210–211del4bp, 327del1bp,
373del1bp, and Trp183Ser (table 1). Seven of these eight
mutations (i.e., 185%) could be detected by SSCP anal-
ysis, and only the Glu388stop mutation (table 1) could
not be detected by SSCP analysis. Mutations were not
detected in the remaining two MEN1 unrelated pro-
bands, from families 3/92 and 5/94 (Trump et al. 1996),
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Figure 2 Detection of eight mutations, in exon 2 (A), exon 5
(B), and exon 9 (C), by SSCP. A, Results of SSCP analysis of the
Gly42Asp (lane d) mutation (table 1), the 10-bp insertion in codons
63–66 (lane e), the 15-bp insertion in codons 34–38 (lane f), and the
11-bp deletion of codons 69–73 (lane g), together with samples from
three unrelated normal controls (lanes a–c). The mutant bands (m),
lanes d–g, differed from the three wild type (WT) bands. B, Results
of SSCP analysis of the deletional insertion at codon 262 (lane c) and
the Lys262stop mutation (lane d) (table 1), together with bands for
samples from two unrelated normal controls (lanes a and b). The
mutant bands (m) differed from the four wild-type (WT) bands (lanes
a and b). C, Results of SSCP analysis of the deletional insertion at
codons 440 and 441 (lane c), the Asp418Asn mutation (lane d), and
the Asp418Asp polymorphism, C/T (lane a) and C/C (lane b), from
two unrelated normal controls. The mutant bands (m) and the poly-
morphic band (P) differed from the wild-type (WT) bands. SSCP anal-
ysis was successful in detecting 85% of the MEN1 mutations.
in whom previous haplotype analysis, using polymor-
phic loci from chromosome 11q13, had demonstrated
cosegregation with MEN1 (European Consortium on
MEN1 1996; Pang et al. 1996). These results indicate
that ∼80% of MEN1 patients are likely to have muta-
tions within the MEN1 coding region and its exon/in-
tron boundaries. Southern and northern blot hybridi-
zation analysis in the 63 MEN1 probands did not detect
additional abnormalities, indicating, respectively, the ab-
sence of genomic deletions and abnormally associated
mRNA transcripts. Thus, a total of 47 mutations, 43 of
which occurred in familial MEN1 and 4 of which oc-
curred in patients with nonfamilial MEN1 (table 1),
were identified in this analysis of 63 unrelated MEN1
patients.
Mutations in MEN1
The 47 mutations occurred throughout the coding ex-
ons of the MEN1 gene and also involved one donor
splice site (table 1 and fig. 1). Thus, 12 nonsense mu-
tations, 21 deletions, 7 insertions, 1 donor splice-site
mutation, and 6 missense mutations were detected. Ap-
proximately 80% of these mutations are likely to result
in a truncatedMEN1 protein and thus to be inactivating,
which is consistent with the tumor-suppressor role pro-
posed for the MEN1 gene (Larsson et al. 1988; Thakker
et al. 1989). Each of these mutations in the 47 MEN1
probands was confirmed and demonstrated to cosegre-
gate with the disease in the 43 families, either by re-
striction-enzyme analysis (fig. 3), ASO hybridization
analysis (fig. 4), or GE (table 1). In addition, the absence
of the DNA sequence abnormalities in 110 alleles from
55 unrelated normal individuals established that these
abnormalities were mutations and unlikely to be poly-
morphisms that would be expected to occur in 11% of
the population. A more detailed examination of the mu-
tations, together with the associated clinical abnormal-
ities, revealed several interesting findings. First, four dif-
ferent mutations (table 1) were found to occur in two
or more unrelated families, as demonstrated by micro-
satellite polymorphism haplotype analysis at the chro-
mosome 11q13 loci D11S1883, D11S457, PYGM, and
D11S449 (data not shown) (European Consortium on
MEN1 1996, 1997c; Pang et al. 1996). The 4-bp de-
letion (CAGT) of codons 210 and 211 in exon 3 was
observed in five unrelated families; the 4-bp deletion
(GTCT) of codons 83 and 84 in exon 2 was observed
in three unrelated families; the Gln349stop in exon 7
was observed in two unrelated families; and the poly(C)7
tract of codons 514–516 in exon 10 was observed to
have insertional or deletional mutations in three unre-
lated families. These four DNA sequences were involved
in 125% of the 47 mutations, suggesting that these co-
dons may be particularly prone to mutations; for ex-
ample, the 4-bp deletion (CAGT) in exon 3 (fig. 1) ac-
counted for 110% of all the mutations and thus may
represent a mutation hot spot in the MEN1 gene. Sec-
ond, correlations between the mutations and the clinical
manifestations of MEN1 could not be established either
between the families (table 1) or even within the families
(figs. 3 and 4); for example, the five unrelated families
with the same 4-bp deletion (CAGT) in codons 210 and
211 were found to have a wide range of MEN1-asso-
Table 1
Mutations, Polymorphisms, and Clinical Details of MEN1 Patients and Families
NUMBERa EXON OR INTRON CODONb BASE CHANGEc
CONFIRMED
BY
NO. OF TUMORS
Parathyroid Pancreaticd Pituitarye Otherf
Nonsense:
1 Exon 2 Arg98stop CGArTGA BglII 2 1 (G) 1 (P) 0
2g Exon 2 Trp126stop TGGrTAG NdeI 2 0 1 (P) 0
3h,i Exon 3 Trp183stop TGGrTGA BstNI 5 3 (G, I, N) 2 (P, Co) 2 (A, C)
4 Exon 3 Glu191stop GAGrTAG ASO 3 1 (G) 0 0
5 Exon 5 Lys262stop AAGrTAG ASO 1 1 (I) 1 (P) 0
6 Exon 7 Trp341stop TGGrTAG BstNI 3 1 (G) 2 (P) 0
7 Exon 7 Gln349stop CAG rTAG BstNI 2 1 (N) 1 (P) 1 (L)
8 Exon 7 Gln349stop CAGrTAG BstNI 3 1 (G) 0 2 (A, L)
9h,j Exon 8 Glu388stop GAGrTAG MnlI 6 2 (G, Gg) 1 (P) 1 (C)
10 Exon 10 Gln453stop CAGrTAG MwoI 1 1 (I) 1 (P) 0
11k Exon 10 Arg460stop CGArTGA DdeI 1 1 (I) 0 0
12 Exon 10 Arg527stop CGArTGA DdeI 6 1 (N) 1 (P) 0
Deletions:
13k Exon 2 69–73: fs42aaX 11 bp: CCCGACCCGCC GE 1 1 (I) 0 0
14h Exon 2 83/84: fs32aaX 4 bp: GTCT GE 2 3 (G, G, Gg) 3 (P, P, N) 1 (A)
15 Exon 2 83/84: fs32aaX 4 bp: GTCT GE 2 1 (G) 0 0
16h Exon 2 83/84: fs32aaX 4 bp: GTCT GE 17 3 (G, G, I) 1 (P) 0
17 Exon 2 90: fs25aaX 2 bp: AT GE 3 2 (G, Gg) 1 (P) 0
18l Exon 2 118/119: del1aa 3 bp: GAA MboII 3 1 (G) 0 0
19 Exon 2 131: fs53aaX 1 bp: C HaeII 2 2 (G, I) 0 0
20 Exon 2 134: fs20aaX 1 bp: C AflII 1 1 (G) 3 (P) 0
21g Exon 3 174: fs9aaX 1 bp: C MnlI 8 3 (G, G, I) 4 (P, P, P, S) 0
22 Exon 3 210/211: fs11aaX 4 bp: CAGT GE 3 1 (G) 0 1 (C)
23 Exon 3 210/211: fs11aaX 4 bp: CAGT GE 2 1 (I) 1 (P) 0
24 Exon 3 210/211: fs11aaX 4 bp: CAGT GE 2 1 (G) 2 (P, N) 0
25 Exon 3 210/211: fs11aaX 4 bp: CAGT GE 2 1 (G) 2 (P) 0
26hi Exon 3 210/211: fs11aaX 4 bp: CAGT GE 3 3 (G, Gg, N) 1 (P) 0
27 Exon 3 214: fs9aaX 1 bp: G MspI 4 1 (G) 1 (P) 0
28l Exon 4 236–239: del3aa 9 bp: TGGCGTTCA GE 2 2 (G, I) 1 (P) 0
29h Exon 7 327: fs53aaX 1 bp: T NlaIV 3 1 (G) 2 (P) 1 (A)
30l Exon 8 358/359: del1aa 3 bp: GAG GE 2 1 (G) 0 0
31h Exon 8 373: fs2aaX 1 bp: C ASO 9 2 (G) 3 (P) 0
32k Exon 9 406–408: fs42aaX 5 bp: CCCTG GE 1 1 (I) 0 0
33 Exon 10 516: fs42aaX 1 bp: C ASO 1 1 (G) 1 (P) 0
Insertions:
34m Exon 2 34–38: ins5aa 15 bp: TGGTGCTCCTTTCCT GE 1 1 (G) 1 (P) 0
35g Exon 2 63–66: fs51aaX 10 bp: CCAGCCCAGC GE 2 1 (G) 0 0
36k Exon 3 162/163: fs22aaX 5 bp: GTTGG GE 1 2 (G, Gg) 0 1 (A)
37 Exon 10 516: fs14aaX 1 bp: C ASO 3 2 (G, N) 1 (P) 0
38 Exon 10 516: fs14aaX 1 bp: C ASO 1 1 (G) 1 (P) 0
Deletional insertions:
39 Exon 5 262: ss,fs18aaX ctagArtcagCC PvuII 3 2 (G) 3 (P) 0
40 Exon 9 440/441: fs5aaX TTrGAAA TaqI 3 1 (G) 1 (N) 0
Donor splice sites:
41g Exon 7 nt 6024: fs1aaX gtgagratgag ASO 2 1 (G) 1 (P) 0
Missense mutations:
42 Exon 2 Gly42Asp GGCrGAC ASO 6 1 (G) 1 (S) 0
43 Exon 3 Ala160Pro GCTrCCT ASO 6 2 (G) 1 (P) 0
44 Exon 3 Ala164Asp GCCrGAC HaeIII 1 2 (G, N) 0 0
45h,i Exon 3 Trp183Ser TGGrTCG BstNI 7 3 (G, I, I) 3 (Co, Co, S) 1 (A)
46g Exon 6 Ala284Glu GCArGAA MboII 2 1 (G) 1 (P) 0
47 Exon 9 Asp418Asn GACrAAC ASO 2 0 0 1 (C)
Polymorphisms:
48 Intron 1 (15) nt2049 C rG (6%) ASO
49 Exon 2 Ser145Ser AGCrAGT (2%) AluI
50 Intron 4 (9) nt5168 GrA (3%) AluI
51 Intron 7 (3) nt6620 CrG (2%) DdeI
52 Exon 9 Asp418Asp GACrGAT (44%) ASO
53 Exon 10 Glu536Glu GAGrGAA (2%) NlaIV
a Refers to location of mutation, as illustrated in figure 1.
b For deletions, insertions, and donor splice-site mutations, “fs” denotes a frameshift, which is followed by the number of amino acids (“aa”) and the stop codon, which is
denoted by “X,” and “ss” denotes splice site alterations.
c Uppercase letters denote an exon sequence, and lowercase letters denote an intron sequence. The percentages denote frequency of heterozygosity.
d G  gastrinoma; I  insulinoma; Gg  glucagonoma; and N  nonfunctional tumor.
e P  prolactinoma; S  somatotrophinoma; Co  corticotrophinoma; and N  nonfunctional tumor.
f A  adrenal cortical tumor; C  carcinoid tumor; and L  lipoma.
g De novo mutation.
h The entire coding region and exon/intron boundaries were examined by DNA sequence analysis.
i Reported previously, by European Consortium on MEN1 (1997b).
j Not detected by SSCP.
k Nonfamilial MEN1.
l Deletion does not cause frameshift.
m Insertion does not cause frameshift.
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Figure 3 Detection of mutation in exon 3 in family 8/89, by restriction-enzyme analysis. SSCP and DNA sequence analysis of individual
II-1 revealed a 1-bp deletion at the second position (GGT) of codon 214 (a). The deletion has caused a frameshift that continues to codon 223
before a stop codon (TGA) is encountered in the new frame (table 1). The 1-bp deletion results in the loss of an MspI restriction-enzyme site
(C/CGG) from the normal (i.e., wild-type [WT]) sequence (a), and this has facilitated the detection of this mutation in the other affected members
(II-4, III-3, and III-4) of this family (b). The mutant (m) PCR product is 190-bp, whereas the wild type (WT) products are 117 and 73 bp (c).
The affected individuals were heterozygous, and the unaffected members were homozygous, for the wild-type sequence. Individuals III-6 and
III-10, who are 40 and 28 years of age, respectively, are mutant-gene carriers who are clinically and biochemically normal; this is due to the
age-related penetrance of this disorder. Individuals are represented as male (squares), female (circles), unaffected (unblackened/unmarked
symbols), affected with parathyroid tumors (symbols with blackened upper-right quadrant), affected with gastrinoma (symbols with blackened
lower-right quadrant), affected with prolactinoma (symbols with blackened upper-left quadrant), and unaffected mutant-gene carriers (symbols
containing a black dot). Individual I-2, who is now deceased but was known to be affected (tumor details are not known), is represented by
a blackened symbol. Below each symbol, the individual’s age either at diagnosis or at the time of the last biochemical screening is given. The
standard-size marker (S), in the form of a 1-kb ladder, is shown. Cosegregation of this mutation with MEN1 in family 8/89, in conjunction
with its absence in 110 alleles from 55 unrelated normal individuals (N1–N3 are shown) indicates that it is not a common DNA sequence
polymorphism.
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Figure 4 Missense mutation in exon 3 of the MEN1 gene in family 16.2/92. SSCP and DNA sequence analysis of individual II-4 revealed
a GrC transversion at codon 160 (a), thus altering the wild-type (WT) sequence GCT, encoding an alanine (A), to the mutant (m) sequence,
CCT, encoding a proline (P). The cosegregation of this mutation (A160P; table 1) in family 16.2/92, as well as its absence from 55 unrelated
normal individuals (N1–N3 are shown), were demonstrated by ASO hybridization analysis (b), since it was not associated with an alteration of
a restriction-enzyme site. Thus, the three unrelated normal individuals (N1–N3), the unaffected spouses II-3 and III-3, and the unaffected individuals
III-1, III-4, III-6, IV-2, and IV-3 were found to have only the wild-type (WT) sequence A160 and none of the mutant (m) sequence (A160P)
and were therefore homozygous for the wild-type sequence. However, all of the affected members (II-1, II-2, II-4, III-2, III-5, and III-7) have
both the wild-type and mutant sequences. In addition, individual IV-1, who is 14 years of age and remains clinically and biochemically unaffected,
is also heterozygous (WT/m), and this individual is thus a mutant-gene carrier who illustrates the age-related penetrance of this autosomal
dominant disorder. The symbols representing the individuals and their ages are as described in figure 3.
ciated tumors (table 1); all the affected members had
parathyroid tumors, but mutations 24–26 (table 1) were
associated with gastrinomas and prolactinomas,
whereas mutation 23 was associated with an insulinoma
and a prolactinoma, and mutation 22 was notably ab-
sent of anterior-pituitary tumors and was associated
with a gastrinoma and carcinoid tumors. Third, a com-
parison between the 47 MEN1 patients (and their fam-
ilies) in whom mutations were detected and the 16
MEN1 patients (and their families) in whom mutations
were not detected revealed no significant phenotypic dif-
ferences. Thus, the distribution of tumors in the patients
and their families with ( tumors) and withoutn  277
( tumors; distribution percentage shown in pa-n  65
rentheses) mutations, respectively, was parathyroid tu-
mors 53% (48%), gastrinomas 16% (14%), insulino-
mas 5% (6%), glucagonomas 2% (1%), nonfunctioning
pancreatic islet–cell tumors 2% (0%), prolactinomas
15% (20%), somatotrophinomas 1% (2%), corticotro-
phinomas 1% (0%), nonfunctioning anterior-pituitary
tumors 1% (1%), adrenal cortical tumors 2% (2%),
carcinoid tumors 1% (4%), and lipomas 1% (2%).
Fourth, five of the mutations (Trp126stop, 174del1bp,
63–66dup10bp, the donor splice-site mutation [nt6024],
and Ala284Glu) were demonstrated to arise de novo (fig.
5), by the use of combined mutational and haplotype
analysis (Pang et al. 1996; European Consortium on
MEN1 1997c) that utilized polymorphic loci from chro-
mosome 11q13. Haplotype studies have previously been
used to predict MEN1 mutant-gene carrier status (Lars-
son et al. 1992, 1995), but our demonstration of the
occurrence of de novo mutations of the MEN1 gene in
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Figure 5 De novo heterozygous nonsense mutation of the MEN1 gene in family 25/90. SSCP and DNA sequence analysis of affected
individual II-4 revealed a GrA transition at codon 126. The wild-type (WT) DNA sequence at codon 126 is TGG coding for a tryptophan
(W) residue, whereas the mutant (m) sequence is TAG encoding a stop (X) signal (a). This nonsense mutation, W126X, resulted in the loss of
an NdeI site, which facilitated its detection in family 25/90 (b). The restriction-enzyme map (c) of the PCR product shows that the wild-type
(WT) DNA sequence, which has one NdeI site, is associated with cleaved PCR products of 105 and 76 bp, whereas the mutant (m), which has
lost the NdeI site, is associated with a PCR product of 181 bp. Analysis of family 25/90 (b) revealed that the affected members II-4 and III-1
were heterozygous for the W126X mutation and that both shared the (1,6,2) haplotype, whose elements were obtained with the polymorphic
loci CNTF, PYGM, and D11S913, respectively. The MEN1 gene is located in the interval between PYGM and D11S913 (European Consortium
on MEN1 1996, 1997a). An examination of the haplotypes (paternal and maternal haplotypes are shown on the left and right, respectively)
in the other family members, who are all unaffected, revealed that individuals II-2, II-6, and II-7 had also inherited the (1,6,2) haplotype from
the deceased unaffected father, I-1 (whose haplotype is shown in square brackets). Thus, individuals II-2, II-6, and II-7 have the haplotype that
is associated with the disease in individuals II-4 and III-1, but they themselves do not have MEN1 or the W126X mutation. These findings
indicate that the W126X mutation is likely to have arisen de novo in individual II-4 and that her affected son III-1 has inherited it. The symbols
representing the individuals and their ages are as described in figure 3. A total of five such de novo mutations (table 1) were identified.
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Table 2
Details on 201 MEN1 Mutant-Gene Carriers
AFFECTED
UNAFFECTED:
GROUP CGroup A Group B
No. of individuals 100 55 46
Male:female ratio 1:1 0.6:1 1.39:1
Mean  SD age (years)a 35  12 25  10 17  10
Age range (years) 11–70 8–46 2–50
a The Mann-Whitney U-test resulted in for group A35P ! 10
compared with group B, for group A comparedwith group29P ! 10
C, and for group B compared with group C; and the28P ! 10
difference-of-means test resulted in for all threeP ! .001
comparisons.
Figure 6 Age distributions (A) and age-related penetrances (B)
of MEN1, determined on the basis of analysis of 201 mutant-gene
carriers. The age distributions were determined for three groups of
MEN1 mutant-gene carriers (table 2) from the 43 families in whom
the mutations were detected (table 1). The 100 members of group A
presented with symptoms, whereas the 55 members of group B were
asymptomatic and were diagnosed by biochemical screening (Thakker
1995; Trump et al. 1996). The 46 members of group C represent those
individuals who are MEN1 mutant-gene carriers (figs. 3 and 4) and
who remain asymptomatic and biochemically normal. The ages in-
cluded for members of groups A, B, and C are those at the onset of
symptoms, at the finding of the biochemical abnormality, and at the
last clinical and biochemical evaluation, respectively. Groups B and C
contained members who were significantly younger ( ) thanP ! 0.001
those in group A (table 2). The younger age of the group C mutant-
gene carriers is consistent with an age-related penetrance for MEN1,
and this was calculated (B) for the first 6 decades. The age-related
penetrances (i.e., the proportion of mutant-gene carriers with mani-
festations of the disease by a given age) rose steadily, from 7% in the
!10-years-old group, to 52%, 87%, 98%, 99%, and 100%, by the
ages of 20, 30, 40, 50, and 60 years, respectively.
110% of the families (table 1) indicates that such hap-
lotype analysis is not reliable (fig. 5) and requires cau-
tious interpretation.
Mutant-Gene Carriers
The identification of mutations in the 43 MEN1 fam-
ilies (table 1), together with their confirmation by either
restriction-enzyme analysis, ASO hybridization analysis,
or GE, facilitated the detection of mutant-gene carriers.
The normal or mutant-gene carrier status (figs. 3 and 4)
was established in 320 members and 73 spouses from
the 43 MEN1 families. Two hundred and one mutant-
gene carriers were identified, and ∼50% of these had
presented with clinical symptoms (group A; table 2 and
fig. 6), 27% were asymptomatic and had been detected
by biochemical screening (group B), and 23% had re-
mained unaffected and were biochemically normal
(group C). The remaining 119 members, together with
the 73 spouses, were all unaffected and normal-gene
carriers. The mean age of group B was significantly
( ) lower than that of group A (table 2), con-P ! .001
firming that biochemical screening is useful in the earlier
detection of the disease. In addition, the mean age of
group C was significantly lower than those of group A
( ) and group B ( ), indicating the non-P ! .001 P ! .001
penetrance of the mutant gene in this younger group.
These results were also confirmed by nonparametric
analysis using the Mann-Whitney U-test. A further anal-
ysis of groups B and C revealed that only 17 of the 55
members of group B, compared with 31 of the 46 mem-
bers of group C ( ; ), were !20 years2x  13.39 P ! .0005
of age, which corresponds to the reported (Trump et al.
1996) age at conversion from an unaffected to an af-
fected phenotype. The age-related penetrance (i.e., num-
ber of MEN1 affected by a given age  [affected 
unaffected mutant-gene carriers by the given age] #
100%) of MEN1 was calculated from the ages of the
201 mutant-gene carriers (fig. 6). This revealed that, al-
though the mutant MEN1 gene is nonpenetrant in all
three mutant-gene carriers !5 years of age, thereafter the
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mutant gene has a high penetrance, being 52%penetrant
by 20 years of age and fully (100%) penetrant by 60
years of age. Thus, the residual risk (i.e., 100  age-
related penetrance %) that an unaffected 20-year-old
mutant-gene carrier will develop MEN1 tumors is 48%,
and these risk assessments will help in the clinical eval-
uation of familial MEN1 patients.
Polymorphisms in the MEN1 gene
Six polymorphisms, which were all detected by SSCP
analysis and confirmed by DNA sequence analysis to-
gether with restriction-enzyme and ASO hybridization
analysis, were observed (table 1) in the MEN1 gene.
Three of these polymorphisms occurred in introns, and
the three polymorphisms that occurred in exons 2, 9,
and 10 all involved the third base of the codon and did
not lead to an alteration of the encoded amino acid. The
range of heterozygosity frequencies of these polymor-
phisms was 2%–44% (table 1), and 175% of all the
polymorphisms were due to the CrT transition of codon
Asp418Asp in exon 9 (fig. 2). The polymorphisms in
codons 145 and 418 have been observed by others
(Agarwal et al. 1997; Chandrasekharappa et al. 1997),
at similar frequencies—0.7% and 54%, respectively. The
importance of these polymorphisms lies in their recog-
nition and distinction from the DNA sequence abnor-
malities that represent mutations. This is of particular
note in the detection of mutations in exon 9, which
contains the Asp418Asp polymorphism that has a
44%–54% heterozygosity frequency in the population,
and the inclusion of appropriate controls in the SSCP
analysis of exon 9 (fig. 2) will help to distinguish between
the polymorphism and mutations.
Discussion
Our results, which have identified 39 different mu-
tations of the MEN1 gene in 47 unrelated patients and
their families, are consistent with our previous predic-
tion, which was based on an absence of common an-
cestral haplotypes and a lack of linkage disequilibrium
in these families (European Consortium on MEN1
1997c). These 47 mutations (table 1) , which are com-
parable to those of a recent report (Agarwal et al. 1997),
consisted of nonsense mutations (26% vs. 22% [all per-
centages are those of the present study vs. those reported
by Agarwal et al. 1997), deletions (45% vs. 51%), in-
sertions (14% vs. 4%), donor splice-site (2% vs. 0%)
mutations, and missense (13% vs. 23%) mutations. The
mutations are scattered throughout the coding region of
the MEN1 gene (fig. 1) and do not correlate with the
phenotypes observed in the MEN1 patients and their
families. The majority (185%) of the 47 mutations are
nonsense mutations , frameshift deletions, or insertions
that are likely to result in a functional loss of theMENIN
protein and are thus in keeping with the proposed role
of the MEN1 gene as a tumor-suppressor gene (Larsson
et al. 1988; Thakker et al. 1989; Thakker 1993). In
addition, the high proportion (60%) of deletions and
insertions that were observed among the 47 MEN1 mu-
tations is similar to that observed (50%) in the tumor-
suppressor retinoblastoma gene (Blanquet et al. 1995;
Lohmann et al. 1996). Furthermore, the independent
and multiple occurrences of these types of MEN1 mu-
tations in codons 83/84, 210/211, and 516, which, re-
spectively, account for 6%, 11%, and 6% of all the 47
mutations, indicate that these may represent hot spots
for small deletions and insertions (table 1). Such dele-
tional and insertional hot spots may be associated with
DNA sequence repeats that may consist of long tracts
of either single nucleotides or shorter elements, ranging
from dinucleotides to octanucleotides (Ripley et al.
1986; Krawczak and Cooper 1991). An examination of
the DNA sequence in the vicinity of codons 83/84 in
exon 2, and codons 210/211 in exon 3 revealed the
presence of CT and CA dinucleotide repeats, respec-
tively, flanking the 4-bp deletions; these would be con-
sistent with a replication-slippage model (Ripley et al.
1986; Cooper and Krawczak 1991; Krawczak and Coo-
per 1991) in which there is misalignment of the dinu-
cleotide repeat during replication, followed by excision
of the resulting 4-bp single-stranded loop. The deletions
and insertions of codon 516 involve a poly(C)7 tract,
and a slipped-strand mispairing model is also the most
likely mechanism to be associated with this mutation
hot spot (Cooper and Krawczak 1991). Thus, theMEN1
gene appears to contain DNA sequences that may render
it susceptible to such deletional and insertional muta-
tions. The mutational diversity within the 2,790 bp of
the MEN1 gene coding region and exon/intron bound-
aries makes mutational screening for MEN1 by a direct
DNA sequencing approach in patients considered to suf-
fer fromMEN1 time consuming and unfeasible.We have
therefore explored the use of the SSCP technique, for
the more rapid screening of MEN1 mutations. Our re-
sults demonstrate that SSCP is a useful, sensitive, and
specific method that is successful in the detection of
185% of the MEN1 mutations. However, the presence
of polymorphismsmay hinder the detection ofmutations
by SSCP, and the use of appropriate controls (fig. 2) is
required in order to facilitate the interpretation of these
results, particularly in the case of exon 9, which contains
a common polymorphism. Our analysis did not detect
mutations in 16 of the 63 unrelated MEN1 probands,
and this may partly be due to the limited sensitivity of
SSCP, but it is important to note that direct DNA se-
quencing of the 2,790 bp of the MEN1-coding region
and exon/intron boundaries also did not detect muta-
tions in 2 of the 10 MEN1 probands. This failure to
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detect mutations is unlikely to be due to genetic heter-
ogeneity, which has been reported in one kindred (Stock
et al. 1997), since cosegregation between MEN1 and
closely flanking polymorphic markers from chromosome
11q13 has been established by previous studies (Euro-
pean Consortium on MEN1 1996, 1997c; Pang et al.
1996) in these families. A more likely explanation is that
these MEN1 patients may harbor mutations in the pro-
moter regions or UTRs, which remain to be investigated.
Our finding of five de novo mutations (table 1), which
represent 110% of the mutations, together with their
inheritance in subsequent generations, has important
clinical implications. Thus, the development of MEN1
tumors in a patient without a family history of the dis-
order does not necessarily imply that the siblings are at
risk, even if they have inherited the chromosome 11q13
haplotype that segregates with the disease (fig. 5). In
addition, the subsequent inheritance of such a de novo
mutation from the parent places the children at risk and
in need of clinical and biochemical evaluation. Our anal-
ysis of the MEN1 mutant-gene carrier status in 320 (165
unaffected and 155 affected) members of 43MEN1 fam-
ilies has helped to determine the age-related penetrance
of this disorder, and this also has important clinical im-
plications. The MEN1 mutant gene has a high pene-
trance (fig. 6) after the age of 5 years and is 52% and
100% penetrant by the ages of 20 years and 60 years,
respectively. In addition, biochemical screening can de-
tect the onset of the disease ∼10 years earlier (table 2
and fig. 6) and before individuals are symptomatic,
thereby providing an opportunity for earlier treatment.
Our data suggest the following possible combined mo-
lecular genetic and clinical approach for MEN1 patients
and their families. Identification of the mutation in a
proband may be undertaken primarily by SSCP analysis,
initially directed at the mutation hot spots in exons 2,
3 and 10 (table 1), and the DNA sequences of any ab-
normalities may be determined. Confirmation of themu-
tation and its subsequent detection, to identify mutant-
gene carriers, may be undertaken either by restriction-
enzyme, ASO, GE, or SSCP analysis. Clinical and bio-
chemical evaluation, as described elsewhere (Thakker
1995; Trump et al. 1996), can then be commenced in
mutant-gene carriers after the age of 5 years and can be
repeated at 6–12-mo intervals (Trump et al. 1996). An
application of this proposed approach will help to iden-
tify those individuals who are at a higher risk and will
enable the earlier detection of MEN1 tumors, thereby
facilitating appropriate genetic counseling and manage-
ment of patients with this inherited endocrine disorder.
Acknowledgements
We are grateful to the Medical Research Council (United
Kingdom) (J. H. D. Bassett, S. A. Forbes, A. A. J. Pannett, S.
E. Lloyd, P. T. Christie, C. Wooding, B. Harding, and R. V.
Thakker), for support; to D. P. Brenton, K. D. Buchanan, L.
Castano, M. S. Croxson, R. H. Greenwood, D. A. Heath, C.
E. Jackson, S. Jansen, K. Lips, A. M. McNicholl, S. B. Patel,
J. R. Paterson, M. H. Samuels, K. A. Sands, S. M. Shalet, and
F. Stewart, for access to the patients and families; and to A.
H-L. Lee, for assistance with the statistical analysis. J.H.D.B.
is anMRC Training fellow. The mutations have been deposited
in the Genome Database (GDB), under the MEN1 entry at:
http://www.gdb.org/gdb-bin/genera/hgd/DBObject/GDB:
120173. The accession numbers for the mutations are:
9686808–9686811, 9787231, 9787241, 9787242, 9787244,
9787245, 9787250–9787256, 9787259, 9787264, 9787267,
9787273, 9787277–9787279, 9787385–9787400; and the ac-
cession numbers for the polymorphisms are: 9787402,
9787406, 9787409, 9787413, 9787416, and 9787418.
References
Agarwal SK, Kester MK, Debelenko LV, Heppner C, Emmert-
BuckMR, Skarulis MC, Doppman JL, et al (1997) Germline
mutations of the MEN1 gene in familial multiple endocrine
neoplasia type 1 and related states. Hum Mol Genet 6:
1169–1175
Blanquet V, Turleau C, Gross-Morand MS, Senamaud-Beau-
fort C, Doz F, Besmond C (1995) Spectrum of germline
mutations in the RB1 gene: a study of 232 patients with
hereditary and non hereditary retinoblastoma. Hum Mol
Genet 4:383–388
Brown MA, Solomon E (1997) Studies on inherited cancers:
outcomes and challenges of 25 years. Trends Genet 13:
202–206
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE,
Collins FS, Emmert Buck MR, Debelenko LV, et al (1997)
Positional cloning of the gene for multiple endocrine neo-
plasia-type 1. Science 276:404–407
Cooper DN, Krawczak M (1991) Mechanisms of insertional
mutagenesis in human genes causing genetic disease. Hum
Genet 87:409–415
European Consortium onMEN1 (1996) Definition of the min-
imal MEN1 candidate area based on a 5 Mb integrated map
of proximal 11q13. Genomics 37:354–365
——— (1997a) Construction of a 1.2 Mb sequence-ready
contig of chromosome 11q13 encompassing the multiple
endocrine neoplasia type 1 (MEN1) gene. Genomics 44:
94–100
——— (1997b) Identification of the multiple endocrine neo-
plasia type 1 gene. Hum Mol Genet 6:1177–1183
——— (1997c) Linkage disequilibrium studies in multiple
endocrine neoplasia type 1 (MEN1). Hum Genet 100:
657–665
Grompe M (1993) The rapid detection of unknown mutations
in nucleic acids. Nat Genet 5:111–117
Krawczak M, Cooper DN (1991) Gene deletions causing hu-
man genetic disease: mechanisms of mutagenesis and the role
of the local DNA sequence environment. Hum Genet 86:
425–441
Larsson C, Calender A, Grimmond S, Giraud S, Hayward NK,
Teh B, Farnebo F, et al (1995) Molecular tools for pre-
244 Am. J. Hum. Genet. 62:232–244, 1998
symptomatic testing in multiple endocrine neoplasia type 1.
J Intern Med 238:239–244
Larsson C, Shepherd J, Nakamura Y, Blomberg C, Weber G,
Werelius B, Hayward N, et al (1992) Predictive testing for
multiple endocrine neoplasia type 1 using DNA polymor-
phisms. J Clin Invest 89:1344–1349
Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold
M (1988) Multiple endocrine neoplasia type 1 gene maps
to chromosome 11 and is lost in insulinoma. Nature 332:
85–87
Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwappach B,
Scheinman SJ, Harding B, et al (1996) A common molecular
basis for three inherited kidney stone diseases. Nature 379:
445–449
Lloyd SE, Pearce SH, Gunther W, Kawaguchi H, Igarashi T,
Jentsch TJ, Thakker RV (1997) Idiopathic low molecular
weight proteinuria associated with hypercalciuric nephro-
calcinosis in Japanese children is due to mutations of the
renal chloride channel (CLCN5). J Clin Invest 99:967–974
Lohmann DR, Brandt B, Ho¨pping W, Passarge E, Horsthemke
B (1996) The spectrum of RB1 germ-line mutations in he-
reditary retinoblastoma. Am J Hum Genet 58:940–949
Pang JT, Lloyd SE, Wooding C, Farren B, Pottinger B, Harding
B, Leigh SE, et al (1996) Genetic mapping studies of 40 loci
and 23 cosmids in chromosome 11p13-11q13, and exclu-
sion of mu-calpain as the multiple endocrine neoplasia type
1 gene. Hum Genet 97:732–741
Pang JT, Thakker RV (1994)Multiple endocrine neoplasia type
1 (MEN1). Eur J Cancer 13:1961–1968
Pearce SH, Trump D, Wooding C, Besser GM, Chew SL, Grant
DB, Heath DA, et al (1995) Calcium-sensing receptor mu-
tations in familial benign hypercalcemia and neonatal hy-
perparathyroidism. J Clin Invest 96:2683–2692
Ripley LS, Clark A, deBoer JG (1986) Spectrum of sponta-
neous frameshift mutations: sequences of bacteriophage T4
rII gene frameshifts. J Mol Biol 191:601–613
Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Bau-
mann G, Hintz RL, et al (1997) A kindred with a variant
of multiple endocrine neoplasia type 1 demonstrating fre-
quent expression of pituitary tumors but not linked to the
multiple endocrine neoplasia type 1 locus at chromosome
region 11q13. J Clin Endocrinol Metab 82:486–492
Thakker RV (1993) The molecular genetics of the multiple
endocrine neoplasia syndromes. Clin Endocrinol (Oxf) 38:
1–14
——— (1995) Multiple endocrine neoplasia type 1. In:
DeGroot L, Besser GM, Burger HG, Jameson JL, Loriaux
DL, Marshall JC, Odel WD, et al (eds) Endocrinology. WB
Saunders, Philadelphia, pp 2815–2831
Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM,
Spurr NK, Besser GM, et al (1989) Association of parathy-
roid tumors in multiple endocrine neoplasia type 1 with loss
of alleles on chromosome 11. N Engl J Med 321:218–224
Thakker RV, Pook MA, Wooding C, Boscaro M, Scanarini M,
Clayton RN (1993) Association of somatotrophinomaswith
loss of alleles on chromosome 11 and with gsp mutations.
J Clin Invest 91:2815–2821
Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buch-
anan KD, Edwards CR, et al (1996) Clinical studies of mul-
tiple endocrine neoplasia type 1 (MEN1). Q J Med 89:
653–669
Varmus HE (1984) The molecular genetics of cellular onco-
genes. Annu Rev Genet 18:553–612
Wermer P (1954) Genetic aspects of adenomatosis of endocrine
glands. Am J Med 16:363–367
